Quantity of suitable sufferers: CDEC discussed the uncertainty in the quantity of people with reasonably extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some people who're classified as having moderate or moderate disorder may have a significant bleeding phenotype, which https://hemgenix94826.blogdanica.com/36049924/hemgenix-an-overview